Itama Ranoraya PT
IDX:IRRA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ID |
I
|
Itama Ranoraya PT
IDX:IRRA
|
609.2B IDR |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
117.1B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
69.7B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
68.2B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
54.3B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
36B AUD |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
64.8B CNY |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64.1B CNY |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.3B USD |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
65.8B HKD |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
Market Distribution
| Min | -220 730.8% |
| 30th Percentile | 0% |
| Median | 3.7% |
| 70th Percentile | 9.8% |
| Max | 190 521.4% |
Other Profitability Ratios
Itama Ranoraya PT
Glance View
PT Itama Ranoraya Tbk operates as a medical devices distributor. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 169 full-time employees. The company went IPO on 2019-10-15. The firm operates in the field of wholesale trading of laboratory equipment, pharmaceutical equipment, and medical devices for humans. The firm carries out its operations through four products, namely the non-electromedical sterile medical devices, in-vitro diagnostic, electromedical sterile medical devices, and other products. Its business segment focuses on in-vitro diagnostic (IVD), medical imaging, surgical instrument and disposable, critical care, blood banking and transfusion, cardiovascular, brain management, cancer, urology, and maternal and neonatal care. Its products include Oneject, Abbott, Terumo, Becton Dickinson (BD), HMD, Vestfrost, Balmed, iGene, AVIMAC, and HemoCue.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Itama Ranoraya PT is 5.5%, which is above its 3-year median of 3.6%.
Over the last 3 years, Itama Ranoraya PT’s Net Margin has decreased from 8.6% to 5.5%. During this period, it reached a low of 0.2% on Jun 30, 2024 and a high of 8.6% on Sep 30, 2022.
